Point of care hematology diagnostics market seen growing to $4.39 billion by 2030

The point of care hematology diagnostics market is projected to grow from $2.9 billion in 2025 to $3.16 billion in 2026, with a longer-term outlook of $4.39 billion by 2030. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth as demand rises for faster blood testing and decentralized care.

Why it matters: - Point of care hematology diagnostics can speed up blood testing near the patient, which helps clinicians make faster decisions in emergency care and other time-sensitive settings. - The market is growing as blood disorders, chronic disease and infectious disease cases increase worldwide. - Rural and resource-poor areas also need testing tools that do not depend on centralized laboratory infrastructure.

What happened: - The Business Research Company released a report on the point of care hematology diagnostics market covering 2026 through 2035. - The market is projected to rise from $2.9 billion in 2025 to $3.16 billion in 2026. - The report forecasts the market will reach $4.39 billion by 2030, implying an 8.6% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Growth in 2025 and 2026 is tied to continued reliance on centralized lab testing, more anemia and blood disorder cases, more hospital emergency visits and the need for rapid diagnostic results. - Limited laboratory infrastructure in rural regions is also supporting demand. - Longer-term growth is supported by the rising prevalence of chronic and infectious diseases, broader adoption of point of care testing programs and improvements in compact hematology analyzers. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The company offered a free sample of the report and a full report.

Between the lines: - The market shift reflects a broader move away from centralized diagnostics toward bedside and decentralized testing. - Portable and handheld analyzers are making blood testing more accessible outside traditional laboratories. - An American Society of Hematology projection cited in the release said global leukemia cases could reach about 519,540 by 2050, underscoring the future burden of blood disorders.

What's next: - The market is expected to keep expanding as healthcare systems add point of care testing to emergency, rural and resource-limited settings. - Technology gains in compact hematology devices are likely to widen use cases and improve test speed and accuracy. - Asia-Pacific’s growth trajectory could narrow the gap with North America over time.

The bottom line: - Faster blood testing, more blood disorders and better portable analyzers are driving a durable growth story for point of care hematology diagnostics.